Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng, Z., Ciavarri, J.P., McRiner, A., Zhao, Y., Zhao, L., Reddy, P.A., Zhang, X., Fischmann, T.O., Whitehurst, C., Arshad Siddiqui, M.(2013) Bioorg Med Chem Lett 23: 2863-2867
- PubMed: 23587425 
- DOI: https://doi.org/10.1016/j.bmcl.2013.03.100
- Primary Citation of Related Structures:  
4JIK - PubMed Abstract: 
Chemistry has been developed to access both imidazo[1,2-a]pyrazines and imidazo[1,2-c]pyrimidines. Small structural modifications in both series led to a switch of potency between two kinases involved in mediating cell cycle checkpoint control, CHK1 and MK2.
Organizational Affiliation: 
Merck Research Laboratories, 320 Bent Street, Cambridge, MA 02141, USA. zhaoyang.meng@merck.com